Hospital and medical care days in pancreatic cancer

about

Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.

P2860

Q38824261-D47ED415-A4AB-4EE2-B148-A060BC9B62DB

P2860

Hospital and medical care days in pancreatic cancer

Item

http://www.wikidata.org/entity/Q36124007

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Hospital and medical care days in pancreatic cancer

@ast

Hospital and medical care days in pancreatic cancer

@en

type

Item

label

Hospital and medical care days in pancreatic cancer

@ast

Hospital and medical care days in pancreatic cancer

@en

prefLabel

Hospital and medical care days in pancreatic cancer

@ast

Hospital and medical care days in pancreatic cancer

@en

P1476

Hospital and medical care days in pancreatic cancer

@en

P2093

Casey A Boyd

http://www.w3.org/2001/XMLSchema#string

Daniel W Branch

http://www.w3.org/2001/XMLSchema#string

James S Goodwin

http://www.w3.org/2001/XMLSchema#string

Kristin M Sheffield

http://www.w3.org/2001/XMLSchema#string

Taylor S Riall

http://www.w3.org/2001/XMLSchema#string

Yimei Han

http://www.w3.org/2001/XMLSchema#string

Yong-Fang Kuo

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data.

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.

End-of-life care in Medicare beneficiaries dying with pancreatic cancer.

Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality.

Surgical management of early-stage pancreatic cancer.

Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma

Comparing hospice and nonhospice patient survival among patients who die within a three-year window.

Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up.

Effect of combined treatment methods on quality of life in patients with pancreatic cancer.

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.

P2888

s10434-012-2326-2

P304

2435-2442

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-012-2326-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221982703

http://www.w3.org/2001/XMLSchema#string

P6179

1029402900

http://www.w3.org/2001/XMLSchema#string

P698

22451235

http://www.w3.org/2001/XMLSchema#string

P932

3407309

http://www.w3.org/2001/XMLSchema#string

Hospital and medical care days in pancreatic cancer

about

P2860

P2860

Hospital and medical care days in pancreatic cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P5875

P6179

P698

P932